ABT vs. MRNA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ABT and MRNA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ABT | MRNA |
|---|---|---|
| Company Name | Abbott Laboratories | Moderna, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Biotechnology |
| Market Capitalization | 230.51 billion USD | 10.46 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | March 17, 1980 | December 7, 2018 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ABT and MRNA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ABT | MRNA |
|---|---|---|
| 5-Day Price Return | 2.44% | 0.75% |
| 13-Week Price Return | -2.29% | 1.89% |
| 26-Week Price Return | 0.49% | -15.76% |
| 52-Week Price Return | 18.36% | -70.11% |
| Month-to-Date Return | 4.95% | -9.03% |
| Year-to-Date Return | 17.09% | -35.33% |
| 10-Day Avg. Volume | 5.80M | 7.78M |
| 3-Month Avg. Volume | 6.66M | 9.92M |
| 3-Month Volatility | 24.22% | 54.60% |
| Beta | 0.70 | 2.05 |
Profitability
Return on Equity (TTM)
ABT
29.93%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
In the upper quartile for the Health Care Equipment & Supplies industry, ABT’s Return on Equity of 29.93% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
MRNA
-27.46%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
MRNA has a negative Return on Equity of -27.46%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
ABT
32.43%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
ABT’s Net Profit Margin of 32.43% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
MRNA
-94.31%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
MRNA has a negative Net Profit Margin of -94.31%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
ABT
17.34%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
ABT’s Operating Profit Margin of 17.34% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
MRNA
-106.34%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
MRNA has a negative Operating Profit Margin of -106.34%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | ABT | MRNA |
|---|---|---|
| Return on Equity (TTM) | 29.93% | -27.46% |
| Return on Assets (TTM) | 17.41% | -21.24% |
| Net Profit Margin (TTM) | 32.43% | -94.31% |
| Operating Profit Margin (TTM) | 17.34% | -106.34% |
| Gross Profit Margin (TTM) | 56.20% | 68.32% |
Financial Strength
Current Ratio (MRQ)
ABT
1.82
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
ABT’s Current Ratio of 1.82 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
MRNA
3.93
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
MRNA’s Current Ratio of 3.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
ABT
0.27
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
ABT’s Debt-to-Equity Ratio of 0.27 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MRNA
0.01
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
MRNA’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
ABT
38.30
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
ABT’s Interest Coverage Ratio of 38.30 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
MRNA
--
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
Interest Coverage Ratio data for MRNA is currently unavailable.
Financial Strength at a Glance
| Symbol | ABT | MRNA |
|---|---|---|
| Current Ratio (MRQ) | 1.82 | 3.93 |
| Quick Ratio (MRQ) | 1.14 | 3.59 |
| Debt-to-Equity Ratio (MRQ) | 0.27 | 0.01 |
| Interest Coverage Ratio (TTM) | 38.30 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ABT
1.73%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
ABT’s Dividend Yield of 1.73% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
ABT
28.42%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
ABT’s Dividend Payout Ratio of 28.42% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | ABT | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 1.73% | 0.00% |
| Dividend Payout Ratio (TTM) | 28.42% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
ABT
16.47
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
In the lower quartile for the Health Care Equipment & Supplies industry, ABT’s P/E Ratio of 16.47 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
MRNA
--
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for MRNA is currently unavailable.
Price-to-Sales Ratio (TTM)
ABT
5.34
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
ABT’s P/S Ratio of 5.34 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
MRNA
3.39
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 3.39 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
ABT
4.68
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
ABT’s P/B Ratio of 4.68 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
MRNA
1.14
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
MRNA’s P/B Ratio of 1.14 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | ABT | MRNA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 16.47 | -- |
| Price-to-Sales Ratio (TTM) | 5.34 | 3.39 |
| Price-to-Book Ratio (MRQ) | 4.68 | 1.14 |
| Price-to-Free Cash Flow Ratio (TTM) | 33.99 | 34.41 |